A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

NCT01682902 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes
Diabetes Mellitus, Type 1

Interventions

DRUG: Faster-acting insulin aspart
DRUG: Faster-acting insulin aspart
DRUG: insulin aspart

Sponsor

Novo Nordisk A/S